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Abstract  
Objective: After aneurysmal subarachnoid haemorrhage (aSAH), extracellular haemoglobin 
(Hb) in the subarachnoid space is bound by haptoglobin, neutralizing Hb toxicity and helping 
its clearance. Two exons in the HP gene (encoding haptoglobin) exhibit copy number 
variation (CNV), giving rise to HP1 and HP2 alleles, which influence haptoglobin expression 
level and possibly haptoglobin function. We hypothesized that the HP CNV associates with 
long-term outcome beyond the first year after aSAH. 
Methods: The HP CNV was typed using quantitative PCR in 1299 aSAH survivors in the 
Genetics of Subarachnoid Haemorrhage (GOSH) Study, a retrospective multicentre cohort 
study with a median follow-up of 18 months. To investigate mediation of the HP CNV effect 
by haptoglobin expression level, as opposed to functional differences, we used rs2000999, a 
single nucleotide polymorphism associated with haptoglobin expression independent of the 
HP CNV. Outcome was assessed using modified Rankin and Glasgow Outcome Scores. SAH 
volume was dichotomized on the Fisher grade. Haemoglobin-haptoglobin complexes were 
measured in cerebrospinal fluid (CSF) of 44 aSAH patients, and related to the HP CNV. 
Results: The HP2 allele associated with a favourable long-term outcome after high-volume, 
but not low-volume aSAH (multivariable logistic regression). However rs2000999 did not 
predict outcome. The HP2 allele associated with lower CSF haemoglobin-haptoglobin 
complex levels. The CSF Hb concentration after high-volume and low-volume aSAH, was 
respectively higher and lower than the Hb-binding capacity of CSF haptoglobin. 
Conclusion: The HP2 allele carries a favourable long-term prognosis after high-volume 
aSAH. Haptoglobin and the Hb clearance pathway are therapeutic targets after aSAH. 
  
Introduction 
 
Extracellular haemoglobin (Hb) is toxic and is immediately neutralized by the protein 
haptoglobin (Hp) as a result of a high affinity binding interaction. The Hp-Hb complex is 
then recognized and endocytosed by the cell surface receptor CD163 1. After aneurysmal 
subarachnoid haemorrhage (aSAH), Hb is released into the cerebrospinal fluid (CSF) from 
damaged erythrocytes trapped in the subarachnoid space, where it is toxic to neurones and 
other cells in the central nervous system 2. The haptoglobin-CD163 Hb clearance mechanism 
is also present in the central nervous system 3. 
The HP gene codes for the α and β chain of haptoglobin. Two codominant HP alleles exist: 
HP1 and HP2; the α chain coding region is duplicated in the HP2 allele, so this is a copy 
number variant (CNV). Three possible HP CNV genotypes: HP1-1, HP2-1 and HP2-2, 
generate the three types of haptoglobin polymers, Hp1-1, Hp2-1 and Hp2-2 4, illustrated in 
Figure 1. In HP1-1 individuals, haptoglobin consists of two chains (α1 and β) linked by one 
disulphide bond. The α1 chain has another free cysteine which leads to dimerization of the 
haptoglobin molecule, so that the only form present in HP1 homozygotes (HP1-1) is the 
haptoglobin dimer. In HP2 homozygotes (HP2-2), two free cysteines in the duplicated α2 
region endow haptoglobin with the capacity to form cyclic polymers of increasing size. In 
heterozygotes (HP2-1), linear polymers of increasing size occur, and the dimer is also 
present.  
In several small studies, the HP CNV was variably associated with short-term to medium-
term outcome after aSAH 5-9, but an individual patient level data analysis did not confirm this 
10. An important consideration is that these studies looked at outcome mostly within the first 
six months after aSAH, and this may not be early enough to allow early brain injury events 
other than Hb, to settle. Another unresolved question relates to the mechanism of action. HP 
alleles are associated with differential haptoglobin expression (HP1-1 > HP2-1 > HP2-2 11) as 
well as haemoglobin-haptoglobin complex scavenging rate by CD163 in vitro 1 12-14. It is not 
clear which of these two consequences of the HP CNV mediate its effect on aSAH outcome.  
To more definitively address these issues, we studied the effect of the HP CNV in the 
Genetic and Observational Subarachnoid Haemorrhage (GOSH) cohort 15 study of long-term 
outcome in aSAH survivors, assessed at a median time from ictus of 18 months, up to 8 
years. We hypothesized that the HP CNV affects long-term outcome after aSAH, and 
investigated how much of this effect was mediated by haptoglobin expression level using 
rs2000999, a single nucleotide polymorphism (SNP) associated with haptoglobin expression 
levels in plasma and tissue (GG > GA > AA), independent of HP CNV 16 17. The combined 
use of rs2000999 and the HP CNV is a useful genetic epidemiological tool to dissect the 
mechanism underlying differences between HP1 and HP2 alleles 18. We sought mechanistic 
evidence supporting our findings by performing biochemical analyses in a separate cohort of 
aSAH patients with available CSF samples. 
 
Subjects and Methods 
GOSH study 
Clinical data and DNA was collected from patients with aSAH enrolled in the GOSH study, 
designed to examine the genetic and clinical characteristics of patients with ruptured and 
unruptured intracranial aneurysms. The GOSH study recruited at 22 tertiary neurosurgical 
centres in the UK between 2011 and 2014. Written informed consent was obtained from 
participants, or next of kin if patients lacked capacity. Recruitment was from inpatient and 
outpatient settings following either a new or previous diagnosis respectively; patients who 
died early after aSAH were not recruited. Standardized case report forms were completed by 
trained stroke research practitioners. The study was approved by the National Research 
Ethics Committee (NRES reference no: 09/H0716/54).  
Outcomes, covariates & definitions 
The primary outcome measure was the modified Rankin scale (mRS) at follow up, 
dichotomized into favourable (mRS 0-1) and unfavourable (mRS 2-6) outcomes, 
administered by qualified research practitioners at the time of assessment. The choice of this 
instrument and dichotomization threshold was based on data availability in this population of 
aSAH survivors. The modified version 19 of the Rankin Scale 20 was used throughout in a 
standardized way, ranging from 0 (no symptoms at all) to 5 (severe disability); mRS 6 (death) 
was added to include mortality 21.  
Covariates included age, sex, admission WFNS score 22, admission Fisher grade 23, 
hydrocephalus, aneurysmal treatment (coiling, clipping, or none), time since ictus, centre, 
smoking pack years, presence or absence of nimodipine treatment, diabetes mellitus, 
hypercholesterolaemia, hypertension, anti-hypertensive medication, and non-SAH related 
disability affecting the primary outcome measure. We defined hypertension, 
hypercholesterolaemia and diabetes mellitus as present if the patient or medical records 
indicated the condition for which either drug treatment, lifestyle, or other advice had been 
provided.  
Control population 
A sample of 927 individuals from the ALSPAC cohort 24 25, previously genotyped for the HP 
CNV (see below), was used as the control population. Plasma haptoglobin level was available 
for 325 of these individuals. It was measured using an immunoturbimetric haptoglobin assay 
(Cobas Integra kit catalogue number 03005593 322, Roche, USA) on a Hitachi Cobas c311 
autoanalyser. In the ALSPAC study, pregnant women resident in Avon, UK with expected 
dates of delivery 1st April 1991 to 31st December 1992 were invited to take part in the study. 
Of the 15,247 pregnancies, there were 14,899 children who were alive at 1 year of age. The 
ALSPAC study website (http://www.bristol.ac.uk/alspac/researchers/our-data/) contains 
details of all the data that is available through a fully searchable data dictionary and variable 
search tool.  Ethical approval for the study was obtained from the ALSPAC Ethics and Law 
Committee and the Local Research Ethics Committees.  
Genotyping 
Detailed genotyping methods for the HP CNV and rs2000999 are in the online 
supplementary methods. 
Biochemistry – high Fisher grade aSAH 
44 Fisher grade III-IV aSAH patients were recruited at the Southampton centre, after 
approval by the National Research Ethics Committee (reference no: 12/SC/0666). CSF was 
obtained from external ventricular drains (EVD) on alternate days from insertion and up to 
two weeks or until the EVD was removed. CSF was spun and frozen within one hour of 
sampling. We did not use CSF samples in the event of an EVD infection. Further details are 
in the online supplementary methods. 
We performed haemoglobin-haptoglobin complex quantification, irrespective of oxidation 
state, using size exclusion ultra-performance liquid chromatography (UPLC) with absorbance 
measurement at 415nm. A 9 point Hb standard curve (0 to 1 mg/ml) was prepared from 
commercially-available lyophilized human Hb (Sigma) reconstituted to 1 g/L in diluent (9 
g/L NaCl, 10 mM EDTA). The concentration of the standard Hb solution was verified 
independently by spectrophotometric quantification at 570 nm using a HemocueTM 
(Hemocue, Sweden). We determined accuracy of the standard curve to be 3.3% using a Hb 
control. 50μL of neat CSF was loaded onto the UPLC column using a running buffer 
consisting of 50 mM Tris and 150 mM NaCl, at pH 7.5. Bound and free Hb peaks’ area under 
the curve was quantified against the Hb standard curve. We quality controlled each assay run 
using three haemoglobin-haptoglobin complex standards (200 μg/ml, 10 μg/ml and 1 μg/ml) 
covering the dynamic range of the assay. We determined haptoglobin phenotype using two 
methods: inspection of serum UPLC chromatograms 26 and non-denaturing Western blot 
using 1:5000 polyclonal rabbit anti-haptoglobin antibody (Sigma, Gillingham, Dorset, UK), 
with 100% concordance. 
CSF/serum albumin ratio (Qalb) was determined after measurement of albumin in serum and 
CSF by rate nephelometry on an IMMAGE Immunochemistry system (Beckman Coulter). 
Qalb was only measured on day 4 post-ictus onwards, to ensure reliability as a measure of 
blood-brain barrier permeability, since preliminary data (not shown) established that three 
days were required for plasma proteins derived from the bleed to be cleared from the 
intrathecal compartment. For this reason, Qalb was only available in 19 aSAH patients. 
Biochemistry – low Fisher grade aSAH 
CSF samples from 8 patients with aSAH Grade I-II were identified retrospectively during an 
ongoing service evaluation of lumbar puncture at the Southampton centre. We excluded cases 
with delayed presentation (>10 days) and traumatic/repeat lumbar punctures. Xanthochromia 
was assessed on a UVIKON XS spectrophotometer using Bio-C software (NorthStar 
Scientific, Bedfordshire, UK). We determined Hb concentration using the Beer-Lambert 
equation, using the net Hb absorbance at 415nm and an extinction coefficient of 141.2 27. 
Statistics 
Statistical analyses were conducted in R and SPSS v22. For all studies, two-tailed hypotheses 
were tested with alpha = 0.05. Detailed statistical methods are in the online supplementary 
methods. 
 
Results 
GOSH study cohort 
GOSH was a study of long-term outcome in SAH survivors, since patients were assessed 
after recovery from the acute phase of SAH, with a median time from ictus of 18 months, up 
to 8 years. A STROBE diagram for the GOSH study participants used in this work is shown 
in Figure 2. The demographic and clinical characteristics of the GOSH cohort are shown in 
Table 1 and Supplementary Figure 1.  
We considered three essential points to ensure our conclusions are valid. First, because of a 
potential selection bias toward survivors or those with better functional outcomes in the 
GOSH study we compared HP genotype frequencies in GOSH versus a young adult control 
population (with minimal bias as a result of disease, country of origin, sex and healthcare) 
from a subset of the ALSPAC (Avon Longitudinal Study of Parents and Children) study, 
previously genotyped for the HP CNV and rs2000999 (n=927). HP CNV and rs2000999 
genotype frequencies in GOSH were as expected, when compared to ALSPAC (χ2=2.19, 
p=0.33 and χ2=0.39, p=0.82, respectively, Supplementary Table 1). Sex was significantly 
different between GOSH versus ALSPAC (70% versus 51% for females respectively, 
χ2=81.15, p<0.0001), but there was no sex difference in the HP CNV and rs2000999 
genotype frequencies in the ALSPAC cohort (χ2=1.39, p=0.50 and χ2=2.31, p=0.32, 
respectively). 
Second, although the HP CNV and rs2000999 are reported to influence haptoglobin 
expression levels in other ethnic groups 17 28 29, we confirmed this in a subset of the ALSPAC 
study in whom the HP CNV, rs2000999 and plasma haptoglobin concentration were all 
available (n=325). In multivariable linear regression, the HP2 allele and rs2000999 A allele 
were both associated with a similar decrease in plasma haptoglobin of 0.21 and 0.16 g/L 
respectively (Supplementary Table 2). 
Third, since the clinical dataset sample size was smaller (n=907) compared to the whole 
GOSH cohort (n=1299) (Table 1), we searched for evidence of bias within the GOSH 
population with clinical data. There was no missingness of any genotype compared to 
ALSPAC within these 907 patients (HP CNV: χ2=1.262, p=0.53 and rs 2000999: χ2=0.228, 
p=0.89, respectively). Moreover the demographic and clinical characteristics of the GOSH 
participants with available clinical data were similar to those of the whole GOSH cohort 
(Table 1). 
HP genotype and long-term outcome 
Next, we investigated the effect of HP genotype on favourable functional outcome (defined 
as modified Rankin scale 0-1) using multivariable logistic regression (Table 2). Favourable 
outcome was predicted by lower aSAH severity assessed by the clinical World Federation of 
Neurosurgical Societies score, lower haemorrhage burden as assessed by Fisher category 
(grades I-II), coiling versus clipping, and absence of hydrocephalus, diabetes, 
hypercholesterolaemia and non-SAH related neurological disability, but not rs2000999. 
There was a strong interaction between the haemorrhage volume (Fisher category) and the 
HP CNV (Tables 2&3, Figure 3A). HP CNV predicted long-term outcome in high Fisher 
category patients (HP2-2 versus HP1-1, Odds ratio of favourable outcome = 2.6, 95% CI 1.4-
4.9, p = 0.003), but not low Fisher category patients (Odds ratio = 2.0, 95% CI 0.71-5.6, p = 
0.194). On the other hand, the Fisher category predicted long-term outcome in HP1-1, but not 
in HP2-2 patients (Tables 2&3, Figure 3A). In essence, the poor prognostic effect of a high 
Fisher category was attenuated by HP2-2, while the Fisher category effect dominated in 
patients with HP1-1.  
There was no evidence of missingness within high or low Fisher category groups that could 
have biased the results, as shown by several analyses: (1) HP CNV genotype frequency was 
not significantly different between low and high Fisher category groups (χ2=1.112, p=0.57); 
(2) HP CNV genotype frequency in the high and low Fisher category groups was not 
significantly different from the ALSPAC control cohort (χ2=1.685, p=0.43 and χ2=0.794, 
p=0.67 respectively); (3) HP genotype frequency of patients excluded from the regression 
due to data availability was not significantly different from that of the included patients (HP 
CNV: χ2=0.378, p=0.97 and rs 2000999: χ2=0.288, p=0.87, respectively) or the ALSPAC 
control cohort (HP CNV: χ2=2.181, p=0.34 and rs 2000999: χ2=0.562, p=0.76, respectively). 
Sensitivity analyses 
A similar pattern was confirmed in five sensitivity analyses: (1) using the Glasgow Outcome 
Scale 30 (Figure 3B); (2) using an alternative dichotomization of the modified Rankin scale, 
with a favourable outcome defined as 0-2 (Figure 3C); (3) using non-dichotomized Fisher 
grade (Supplementary Figure 2); (4) using multiple imputation on the whole GOSH cohort 
(Supplementary Table 4); and (5) analyses across decreasing follow-up intervals (Table 4). 
The finding that the HP2 allele predicted long-term outcome in high Fisher category patients 
was robust to decreasing follow-up time intervals, except at one year. This was not due to 
smaller sample sizes since the 3-8 epoch had a similar sample size to the ≤ 1 year epoch. 
Biochemical studies 
Although the HP CNV and rs2000999 affect haptoglobin expression level to a similar extent 
18, only the HP CNV associated with outcome after aSAH, suggesting that functional 
differences between Hp1-1 and Hp2-2 proteins, perhaps relating to Hb scavenging rather than 
expression, are likely to be more important. Hence we measured haemoglobin-haptoglobin 
complexes in serial CSF samples taken from an external ventricular drain after high-grade 
aSAH (Fisher grade III-IV, n=44, Supplementary Table 3), using ultra-performance size-
exclusion liquid chromatography coupled with absorption detection at 415nm. The patients’ 
HP CNV status was: HP1-1=9, HP2-1=19, HP2-2=16. All samples contained haemoglobin-
haptoglobin complexes, in keeping with saturation of membrane CD163 binding sites in the 
brain after aSAH, as previously reported 3. The CSF concentration of haemoglobin-
haptoglobin complexes was compared across HP CNV types using ANOVA, and was lower 
in HP2-2 patients than those with HP1-1 (Figure 4A). In an analysis of covariance of CSF 
haemoglobin-haptoglobin complex concentration across HP CNV genotype, controlling for 
age, sex, clot volume, and CSF/serum albumin quotient, the HP CNV genotype was the 
dominant determinant, explaining 50% of variance in CSF haemoglobin-haptoglobin 
complex concentration, out of a total of 57% by the whole model (p=0.001, Figure 4B).  
The effect of the HP CNV on long-term outcome varied with the volume of aSAH. It is 
known that haptoglobin in the CSF is present at very low concentrations in both healthy 
controls and after aSAH, such that after high-grade aSAH, haptoglobin is saturated with Hb 3. 
We confirmed this observation in our patients; median CSF haptoglobin was 0.29µM 
(interquartile range: 0.11-0.58µM, expressed as Hb dimer binding capacity) and it was fully 
saturated with Hb. The low haptoglobin concentration in the CSF has a potential to set up a 
situation where the system could operate differently depending on Hb concentration. After 
low-volume aSAH, Hb concentration may be low such that there is sufficient haptoglobin to 
bind all the Hb, while after high-volume aSAH, the system may be overwhelmed. Ideally one 
would study haptoglobin saturation with Hb in the CSF from high and low Fisher aSAH 
patients. However it was challenging to prospectively identify CSF samples from Fisher I-II 
aSAH patients, since CSF drainage has no place in their clinical management. Nevertheless, 
we were able to study retrospective data from Fisher I-II aSAH cases referred for 
spectrophotometric testing for xanthochromia (median days post-ictus = 2 days, interquartile 
range 1-3 days, Supplementary Table 3). The median Hb concentration in the CSF of patients 
with Fisher III-IV aSAH was 2.58µM (interquartile range: 1.07-13.5µM, n=44), i.e. well 
above the 0.29µM Hb-binding capacity of Hp. In the CSF of patients with Fisher I-II aSAH, 
the mean Hb CSF concentration was 0.053µM (0.032-0.189µM, n=8), i.e. well below 
0.29µM (p < 0.001, Figure 4C). These findings provide a potential explanation for the 
observation that the HP2-2 genotype is only protective after high-volume aSAH. 
 
Discussion 
This is the largest study of HP genotype and outcome after SAH, and provides a number of 
novel insights. The HP allele does not associate with outcome after aSAH if this is measured 
early after aSAH, within the first year 10. We argue that the HP influence on outcome is 
overshadowed by the effect of early brain injury on outcome in the first year after aSAH, i.e. 
it takes longer than previously thought for early brain injury effect to settle. In support of this 
interpretation, we show that the HP2 allele’s association with good functional outcome was 
only detectable two years or more after aSAH (Table 4). 
We found that after low-volume aSAH, CSF Hb concentration was within the Hb-binding 
capacity of CSF haptoglobin, while it exceeded this concentration in high-volume patients. 
Hence high-volume patients have unbound Hb available to impact on outcome, so that 
functional differences between HP genotypes makes a difference after high-volume aSAH. 
Collectively, these data suggest that the association of the HP2 allele on long-term outcome 
after aSAH depends on the haemorrhage burden (Fisher category) and Hb concentration in 
the CSF. In the presence of high CSF Hb concentration, the HP2 allele is superior to the HP1 
allele, being associated with lower haemoglobin-haptoglobin complexes in the CSF and a 
better functional outcome. At low haemorrhage burden and CSF Hb concentration, the HP 
CNV does not associate with long-term outcome. That the differential clinical effect of the 
HP CNV is mediated via mechanisms other than haptoglobin expression level is supported by 
the fact that while both the HP CNV and rs2000999 associate with haptoglobin expression, 
only the HP CNV is linked to long-term outcome. A recent study has found that lumbar CSF 
drainage improves outcome in high but not low modified Fisher grade patients 31, which 
resonates with our findings here. 
There is conflicting evidence in the literature regarding the relative efficacy of haptoglobin 
types in CD163-mediated cellular uptake of haemoglobin-haptoglobin complexes. Although 
one study suggested that haemoglobin-haptoglobin complex uptake is better with Hp1-1 12, 
two subsequent studies have reported that Hp2-2 is better 13 14 which would be in keeping 
with the results from biochemical binding studies 1 12. Although the differences between these 
in vitro studies may be due to experimental technicalities, the conflicting results suggest that 
the difference between the two alleles may not be marked. However it is possible that a subtle 
difference between HP1 and HP2 allele protein products is amplified in the brain where the 
low CD163 expression level is a limiting factor in Hb scavenging 3 32. The low haemoglobin-
haptoglobin complex concentration in the CSF of HP2 carriers could be due to lower 
haptoglobin expression in the CSF, as would be expected for the HP2 allele. However lower 
CSF haptoglobin levels in HP2 carriers would carry a worse outcome after SAH, not a better 
one. Also rs2000999 did not associate with outcome. It is therefore more likely that 
haemoglobin-haptoglobin complex scavenging after high-grade SAH is better in HP2 
carriers, versus HP1. The higher valency of Hp2-containing complexes likely improves 
clustering of CD163 receptors 33. The larger size of the Hb-Hp2-2 complexes (compared to 
the smaller Hb-Hp1-1 complexes), may also prevent their entry into the brain parenchyma, 
thereby reducing neurotoxicity. These explanations need further careful study.  
The association of the HP2 allele with good long-term outcome in high Fisher grade patients 
is in contrast to the findings from a mouse model of SAH where HP2-2-transgenic animals 
had a worse outcome compared to HP1-1 wild-type mice 34. It is important to bear in mind 
that there are marked differences in the biochemistry of Hb scavenging between mouse and 
man. In particular, the haptoglobin receptor CD163 has a higher affinity for haemoglobin-
haptoglobin complexes in man, but not in mice 35. Also, human CD163 is cleaved during 
inflammation, releasing soluble CD163, but this does not happen with mouse CD163 36. For 
these two reasons, differences in haptoglobin types with respect to CD163 binding are more 
likely to be important in humans than in mice.  
In conclusion, in patients with aSAH who have a high haemorrhage burden, the HP2 allele is 
associated with favourable long-term functional outcome, possibly via improved 
haemoglobin-haptoglobin complex clearance. Our findings suggest that preclinical trials of 
haptoglobin supplementation should consider testing Hp1-1 versus Hp2-2. Also, the HP CNV 
genotype and its interaction with Fisher grade should be considered when designing 
prognostic algorithms and clinical trials in aSAH.  
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Table 1. GOSH demographics and clinical characteristics: whole cohorta and clinical outcome 
datasetb. Notes: Mean & rangec, number and %d, median & rangee, % reported is of available dataa 
or of total datab, NA: DNA not available.  
 
 
Entire aSAH 
cohorta 
Missingness 
analysisa 
Outcome analysisb 
    
Number 1729 1299 907 
Age (years)c 53.2 (12-92) 53 (16-92) 53 (19-92) 
Sexd 
Male 
female 
 
514 (29.7%) 
1215 (70.3%) 
 
385 (30%) 
914 (70%) 
 
261 (29%) 
646 (71%) 
WFNSd 
1 
2 
3 
4 
5 
 
950 (57.2%) 
364 (21.9%) 
71 (4.3%) 
171 (10.3%) 
104 (6.3%) 
 
711 (56.9%) 
278 (22.3%) 
54 (4.3%) 
129 (10.3%) 
77 (6.2%) 
 
509 (56%) 
210 (23.2%) 
45 (5%) 
86 (9.5%) 
57 (6.3%) 
Fisher graded 
1 
2 
3 
4 
 
139 (8.9%) 
466 (29.9%) 
347 (22.3%) 
607 (38.9%) 
 
94 (8.0%) 
363 (30.8%) 
266 (22.5%) 
457 (38.7%) 
 
74 (8.1%) 
280 (30.9%) 
206 (22.7%) 
347 (38.3%) 
Hydrocephalusd 
Present 
Absent 
 
608 (35.2%) 
1121 (64.8%) 
 
459 (35%) 
840 (65%) 
 
324 (36%) 
583 (64%) 
Aneurysmal managementd 
Coiled 
Clipped 
Supportive 
 
1367 (79.1%) 
297 (17.2%) 
65 (3.7%) 
 
991 (78%) 
265 (21%) 
14 (1%) 
 
720 (79%) 
180 (20%) 
7 (1%) 
Aneurysm locationd 
Anterior circulation 
Posterior circulation 
Not classified 
 
1411 (81.61%) 
211 (12.2%) 
107 (6.19%) 
 
1087 (84%) 
177 (14%) 
35 (3%) 
 
774 (85%) 
126 (14%) 
7 (1%) 
Nimodipined 
Administered 
Not administered 
 
1612 (93.2%) 
117 (6.8%) 
 
1211 (93%) 
88 (7%) 
 
870 (96%) 
37 (4%) 
Time since ictus (months)e 15 (0-519) 18 (0-519) 17 (0-96) 
Hypertensiond    
Present 
Absent 
542 (31.4%) 
1187 (68.7%) 
383 (29%) 
916 (71%) 
274 (30%) 
633 (70%) 
Diabetes mellitusd 
Present 
Absent 
 
 
69 (4%) 
1660 (96%) 
 
 
53 (4%) 
1246 (96%) 
 
 
34 (4%) 
873 (96%) 
Smoking (pack-years)c 20.9 (0-137) 17 (0-137) 17 (0-137) 
Hypercholesterolemiad 
Present 
Absent 
 
350 (20.2%) 
1379 (79.8%) 
 
262 (20%) 
1026 (80%) 
 
196 (22%) 
711 (78%) 
Other disabilityd 
Present 
Absent 
 
116 (7%) 
1151 (93%) 
 
92 (7%) 
1146 (93%) 
 
64 (7%) 
843 (93%) 
HP CNV genotypea 
HP1-1 
HP2-1 
HP2-2 
 
NA 
NA 
NA 
 
205 (16%) 
612 (47%) 
481 (37%) 
 
142 (16%) 
424 (47%) 
341 (37%) 
rs2000999 genotypea 
AA 
AG 
GG 
 
NA 
NA 
NA 
 
57 (5%) 
379 (29%) 
854 (66%) 
 
39 (4%) 
270 (30%) 
598 (66%) 
 
Table 2. Logistic regression model for primary outcome (favourable mRS 0-1). Logistic regression model fit was excellent (log-likelihood chi-squared 
test p<10-27; Hosmer & Lemeshow test p=0.305). The model explained 32% of the variance in functional outcome. WFNS = World Federation of 
Neurosurgical Societies; OR = Odds ratio; CI = confidence interval. 
 p 
(overall effect) OR 95% CI Contrast (vs reference) 
p 
(contrast) 
       
Age 0.490 0.995 0.980 1.010   
Sex 0.446 1.156 0.797 1.677 Female (vs male)   
WFNS <0.001 4.787 2.404 9.531 WFNS 1 (vs 5) <0.001 
Hydrocephalus <0.001 2.004 1.386 2.897 Absent (vs present) <0.001 
Aneurysmal treatment 0.005 1.817 1.194 2.763 Coiling vs clipping 0.014 
Nimodipine 0.111 1.914 0.862 4.249 Given vs not given  
Followup time 0.121 1.007 0.998 1.015   
Centre <0.001     <0.001 
Hypertension 0.761 0.951 0.650 1.392 Absent (vs present)  
Diabetes 0.035 2.529 1.068 5.986 Absent (vs present)  
Smoking (pack-years) 0.441 1.003 0.995 1.012   
Hypercholesterolemia 0.023 1.636 1.070 2.502 Absent (vs present)  
Non-aSAH related disability <0.001 5.536 2.984 10.271 Absent (vs present)  
rs2000999 0.359 1.469 0.646 3.341 GG vs AA 0.154 
Fisher x HP 0.013      
Fisher 0.009 4.105 1.428 11.806 Low vs high Fisher in HP1-1  
HP 0.011 2.602 1.381 4.904 HP2-2 vs HP1-1 at high Fisher 0.003 
Table 3. The effects of haemorrhage burden (Fisher category) and HP CNV on favourable outcome 
(mRS 0-1) are mutually dependent. 
 
The impact of HP CNV on favourable outcome (mRS 0-1) depends on Fisher grade 
  
n (HP1-1 versus HP2-2) OR 95% C.I. p 
      
Low Fisher (I-II) 181 (52 vs 129) 1.991 0.705 5.628 0.194 
High Fisher (III-IV) 302 (90 vs 212) 0.384 0.204 0.724 0.003 
      
n (HP2-1 versus HP2-2) OR 95% C.I. p 
      
Low Fisher (I-II) 302 (173 vs 129) 1.433 0.771 2.665 0.255 
High Fisher (III-IV) 463 (251 vs 212) 0.660 0.418 1.043 0.075 
      
 n (HP2-1 versus HP1-1) OR 95% C.I. p  
      
Low Fisher (I-II) 225 (173 vs 52) 0.502 0.178 1.419 0.194 
High Fisher (III-IV) 341 (251 vs 90) 1.718 0.951 3.102 0.073 
 
The impact of Fisher grade on favourable outcome (mRS 0-1) depends on the HP CNV 
 
 n (low versus high Fisher) OR 95% C.I. p 
  
HP1-1 142 (52 vs 90) 4.105 1.428 11.806 0.009 
HP2-2 341 (129 vs 212) 1.262 0.703 2.265 0.435 
 
  
Table 4. Sensitivity analysis at different follow-up intervals. Findings are largely robust, except at 
shorter follow-up of one year or less. 
A. For mRS 0-1 
Sample size Time since ictus HP CNV1 HP CNV1 rs20009992 
  Low Fisher grade High Fisher grade  
  OR, 95% CI, p value 
907 ≤ 8 years 0.5, 0.2-1.4, 0.194  2.6, 1.4-4.9, 0.003 NS, p = 0.359 
863 ≤ 6 years 0.4, 0.1-1.2, 0.106 2.8, 1.5-5.4, 0.002 NS, p = 0.263 
776 ≤ 4 years 0.5, 0.2-1.5, 0.193 2.8, 1.4-5.4, 0.003 NS, p = 0.258 
575 ≤ 2 years 0.5, 0.2-1.7, 0.258 2.0, 1.1-3.4, 0.100 NS, p = 0.807 
349 ≤ 1 year 0.5, 0.1-2.4, 0.367 1.6, 0.5-5.1, 0.415 NS, p = 0.967 
204 ≤ 6 months 0.2, 0.02-1.5, 0.114 0.8, 0.1-4.8, 0.777 NS, p = 0.929 
87 ≤ 3 months NS, p = 1.0 NS, p = 1.0 NS, p = 1.0 
     
332 3-8 years 0.4, 0.04-4.3, 0.404 4.4, 1.3-14.4, 0.014 NS, p = 0.215 
 
B. For GOS 5 
Sample size Time since ictus HP CNV1 HP CNV1 rs20009992 
  Low Fisher grade High Fisher grade  
  OR, 95% CI, p value 
907 ≤ 8 years 0.3, 0.1-1.0, 0.045  2.7, 1.4-5.3, 0.003 NS, p = 0.415 
863 ≤ 6 years 0.3, 0.1-1.0, 0.047 2.8, 1.4-5.5, 0.002 NS, p = 0.472 
776 ≤ 4 years 0.3, 0.1-1.3, 0.119 2.9, 1.4-5.9, 0.003 NS, p = 0.532 
575 ≤ 2 years 0.3, 0.1-1.4, 0.132 2.8, 1.2-6.4, 0.019 NS, p = 0.627 
349 ≤ 1 year 0.4, 0.1-2.7, 0.370 2.8, 0.7-10.6, 0.128 NS, p = 0.856 
204 ≤ 6 months 0.09, 0.01-1.5, 0.91 6.4, 0.5-87, 0.165 NS, p = 0.677 
87 ≤ 3 months NS, p = 1.0 NS, p = 1.0 NS, p = 1.0 
     
332 3-8 years 0.0, 0.0-0.0, 0.998 4.0, 1.1-15.1, 0.039 NS, p = 0.512 
 
1 HP2-2 versus HP1-1, for favourable outcome  
2 rs2000999 G versus A, for favourable outcome 
Figures 
 
 
Figure 1. Haptoglobin types: Hp1-1, Hp2-1 and Hp2-2. The HP gene codes for the α and β chain of 
Hp. Two codominant HP alleles exist: HP1 and HP2; the α chain coding region is duplicated in the 
HP2 allele, so this is a copy number variant (CNV). Three possible HP CNV genotypes: HP1-1, 
HP2-1 and HP2-2, generate three types of haptoglobin polymers, Hp1-1, Hp2-1 and Hp2-2. 
  
 Figure 2. STROBE diagram 
 
  
Figure 3. HP association with outcome after aSAH depends on clot volume. A: The mean predicted probability of favourable outcome (mRS: 0-1) ± 
standard deviation, by HP CNV and Fisher category. The HP CNV predicted long-term outcome in high Fisher category patients (HP2-2 versus HP1-
1, Odds ratio (OR) of favourable outcome = 2.6, 95% CI 1.4-4.9, p = 0.007). In the low Fisher category, there is a trend suggesting that the reverse 
might be happening (i.e. that HP1-1 confers a favourable outcome versus HP2-2), but this was not significant (OR=2.0, 95% CI 0.71-5.6, p = 0.194), 
despite the lower standard deviations in the low Fisher category. B: The mean predicted probability of favourable outcome (GOS: 5) ± standard 
deviation, by HP CNV and Fisher category. At high Fisher grade: p=0.003, OR=2.74 (95% CI: 1.4-5.3) for HP2-2 versus HP1-1. At low Fisher grade: 
p=0.045, OR=0.26 (95% CI: 0.07-0.97) for HP2-2 versus HP1-1. C: The mean predicted probability of favourable outcome (mRS: 0-2) ± standard 
deviation, by HP CNV and Fisher category. At high Fisher: p=0.002, OR=3.26 (95% CI: 1.5-6.9) for HP2-2 versus HP1-1. At low Fisher: p=0.149, 
OR=0.211 (95% CI: 0.03-1.7) for HP2-2 versus HP1-1. 
  
  
Figure 4. Haptoglobin-haemoglobin complex scavenging in CSF varies with the HP CNV in high-grade aSAH. A. ANOVA of CSF haemoglobin-
haptoglobin complex concentration across HP CNV types (n=44, p=0.003, F=6.58, df=43). Post-hoc group comparisons were performed using 
Bonferroni adjustment. Plot shows means ± standard deviation. B. ANCOVA of CSF haemoglobin-haptoglobin complex concentration across HP 
CNV types controlling for age, clot volume, CSF/serum albumin quotient and sex (n=19, p=0.006 and partial eta squared=0.566 for model). We 
performed group comparisons with Bonferroni adjustment. The plot shows estimated marginal means ± 95% confidence intervals. C. CSF Hb 
concentration in Fisher grade I-II (n=8) and III-IV (n=44). Plot shows medians ± interquartile range. Mann-Whitney U test. Dotted line represents the 
Hb-binding capacity of haptoglobin in CSF. 
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Subjects and Methods 
GOSH study 
Clinical data and DNA was collected from patients with aSAH enrolled in the GOSH study, 
designed to examine the genetic and clinical characteristics of patients with ruptured and unruptured 
intracranial aneurysms. The GOSH study recruited at 22 tertiary neurosurgical centres in the UK 
between 2011 and 2014. Written informed consent was obtained from participants, or next of kin if 
patients lacked capacity. Recruitment was from both inpatient and outpatient neurovascular clinics 
following either a new or previous diagnosis respectively; patients who died early after aSAH were 
not recruited. Standardized case report forms were completed by trained stroke research 
practitioners. The study was approved by the National Research Ethics Committee (NRES reference 
no: 09/H0716/54).  
Outcomes, covariates & definitions 
The primary outcome measure was the modified Rankin scale (mRS) at follow up, dichotomized 
into favourable (mRS 0-1) and unfavourable (mRS 2-6) outcomes, administered by qualified 
research practitioners at the time of assessment. The choice of this instrument and dichotomization 
threshold was based on data availability in this population of aSAH survivors. The modified version 
1 of the Rankin Scale 2 was used throughout in a standardized way, ranging from 0 (no symptoms at 
all) to 5 (severe disability); mRS 6 (death) was added to include mortality 3.  
Covariates included age, sex, admission WFNS score 4, admission Fisher grade 5, hydrocephalus, 
aneurysmal treatment (coiling, clipping, or none), time since ictus, centre, smoking pack years, 
presence or absence of nimodipine treatment, diabetes mellitus, hypercholesterolaemia, 
hypertension, anti-hypertensive medication, and non-SAH related disability affecting the primary 
outcome measure. We defined hypertension, hypercholesterolaemia and diabetes mellitus as present 
if the patient or medical records indicated the condition for which either drug treatment, lifestyle, or 
other advice had been provided.  
Control population 
A sample of 927 individuals from the ALSPAC cohort 6 7, previously genotyped for the HP CNV 
(see below), was used as the control population. Plasma haptoglobin level was available for 325 of 
these individuals. It was measured using an immunoturbimetric haptoglobin assay (Cobas Integra 
kit catalogue number 03005593 322, Roche, USA) on a Hitachi Cobas c311 autoanalyser. In the 
ALSPAC study, pregnant women resident in Avon, UK with expected dates of delivery 1st April 
1991 to 31st December 1992 were invited to take part in the study. Of the 15,247 pregnancies, there 
were 14,899 children who were alive at 1 year of age. The ALSPAC study website 
(http://www.bristol.ac.uk/alspac/researchers/our-data/) contains details of all the data that is 
available through a fully searchable data dictionary and variable search tool.  Ethical approval for 
the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research 
Ethics Committees.  
GOSH HP CNV genotyping 
We performed HP CNV genotyping using a quantitative polymerase chain reaction (qPCR) method 
8. The assay amplified a region in the 5` terminal of the HP gene’s first exon as an internal control 
(HP5`), and the breakpoint of the HP duplication (HP2). The HP2/HP5` ratio (theoretically either 0, 
1, or 2) was used to determine the genotype as HP1-1, HP2-1 or HP2-2 respectively. Samples were 
run in triplicate, and triplicates with a HP2/HP5`ratio coefficient of variation >10% were re-
assayed. A second method of HP genotyping by PCR 9 was performed on samples with HP2/HP5’ 
ratio values between 0.4619 and 0.6214, in order to confirm the HP CNV genotype. For quality 
control, we randomly selected 10% of samples not previously subject to this typing method and 
genotyped them via this method, comparing results to the qPCR technique. 98% concordance was 
observed; we repeated discordant samples using both assays and found them to be in agreement. 
There was only one failed genotype call, i.e. a 99.92 % call rate. 
GOSH rs2000999 genotyping 
rs2000999 has been shown to be associated with haptoglobin levels in the plasma and its level of 
expression in tissue, as exemplified by adipose tissue10. Since rs2000999 is downstream of the HP 
gene, its effect is probably mediated via linkage disequilibrium with upstream variations, such as 
rs3528391111. We genotyped patients for rs2000999 status using Kompetitive Allele Specific PCR 
(KASP), a fluorescence resonant energy transfer (FRET) PCR based assay (LGC Genomics 
Limited, Hertfordshire, UK). Genotypes were called automatically by SNPviewer v4.0 (LGC 
Genomics Ltd., Hertfordshire, UK). We genotyped cases marked equivocal by the software (n=51) 
using a Taqman assay (C_11439054_10, ThermoFisher, USA). Cluster plots were viewed using 
Taqman genotyping software (v1.4, Applied Biosystems, USA) to call genotypes. For quality 
control, 30 other cases typed by the KASP assay and successfully called by SNPviewer were cross-
checked with the Taqman assay and 100% concordance was observed. Nine out of 1299 samples 
failed to be called by both KASP and Taqman methods, resulting in a 99.31% call rate.  
ALSPAC HP CNV genotyping 
The HP CNV of ALSPAC children was typed using amplification ratio control system (ARCS), a 
validated liquid phase high-throughput assay for quantifying gene copy number 12. Out of 1056 
samples, 927 were successfully called (ie 87.8%). 
ALSPAC rs2000999 genotyping 
ALSPAC children were genotyped using the Illumina HumanHap550 quad chip genotyping 
platforms by 23andme subcontracting the Wellcome Trust Sanger Institute, Cambridge, UK and the 
Laboratory Corporation of America, Burlington, NC, US. The resulting raw genome-wide data were 
subjected to standard quality control methods. Individuals were excluded on the basis of sex 
mismatches; minimal or excessive heterozygosity; disproportionate levels of individual missingness 
(>3%) and insufficient sample replication (IBD < 0.8). Population stratification was assessed by 
multidimensional scaling analysis and compared with Hapmap II (release 22) European descent 
(CEU), Han Chinese, Japanese and Yoruba reference populations; all individuals with non-European 
ancestry were removed. rs2000999 genotype was extracted from this dataset. 
Biochemistry – high Fisher grade aSAH 
44 Fisher grade III-IV aSAH patients were recruited at the Southampton centre, after approval by 
the National Research Ethics Committee (reference no: 12/SC/0666). CSF was obtained from 
external ventricular drains (EVD) on alternate days from insertion and up to two weeks or until the 
EVD was removed. CSF was spun and frozen within one hour of sampling. We did not use CSF 
samples in the event of an EVD infection. 
We performed haemoglobin-haptoglobin complex quantification, irrespective of oxidation state, 
using size exclusion ultra-performance liquid chromatography (UPLC) with absorbance 
measurement at 415nm. A 9 point Hb standard curve (0 to 1 mg/ml) was prepared from 
commercially-available lyophilized human Hb (Sigma) reconstituted to 1 g/L in diluent (9 g/L 
NaCl, 10 mM EDTA). The concentration of the standard Hb solution was verified independently by 
spectrophotometric quantification at 570 nm using a HemocueTM (Hemocue, Sweden). We 
determined accuracy of the standard curve to be 3.3% using a Hb control. 50μL of neat CSF was 
loaded onto the UPLC column using a running buffer consisting of 50 mM Tris and 150 mM NaCl, 
at pH 7.5. Bound and free Hb peaks’ area under the curve was quantified against the Hb standard 
curve. We quality controlled each assay run using three haemoglobin-haptoglobin complex 
standards (200 μg/ml, 10 μg/ml and 1 μg/ml) covering the dynamic range of the assay. We 
determined haptoglobin phenotype using two methods: inspection of serum UPLC chromatograms 
13 and non-denaturing Western blot using 1:5000 polyclonal rabbit anti-haptoglobin antibody 
(Sigma, Gillingham, Dorset, UK), with 100% concordance. 
CSF/serum albumin ratio (Qalb) was determined after measurement of albumin in serum and CSF 
by rate nephelometry on an IMMAGE Immunochemistry system (Beckman Coulter). Qalb was 
only measured on day 4 post-ictus onwards, to ensure reliability as a measure of blood-brain barrier 
permeability, since preliminary data (not shown) established that three days were required for 
plasma proteins derived from the bleed to be cleared from the intrathecal compartment. For this 
reason, Qalb was only available in 19 aSAH patients. 
Biochemistry – low Fisher grade aSAH 
CSF samples from 8 patients with aSAH Grade I-II were identified retrospectively during an 
ongoing service evaluation of lumbar puncture at the Southampton centre. We excluded cases with 
delayed presentation (>10 days) and traumatic/repeat lumbar punctures. Xanthochromia was 
assessed on a UVIKON XS spectrophotometer using Bio-C software (NorthStar Scientific, 
Bedfordshire, UK). We determined Hb concentration using the Beer-Lambert equation, using the 
net Hb absorbance at 415nm and an extinction coefficient of 141.2 14. 
Clot volume 
Computed tomographic (CT) imaging of the head was available for 38 out of the 44 patients with 
high-grade aSAH providing CSF; there was no significant difference in the demographics and 
baseline characteristics of these 38 patients compared to the whole cohort (data not shown). 
Volumetric blood clot volume was quantified using MIPAV (Medical Image Processing, Imaging 
and Visualization) v7.2. We only included CT images in the analysis if acquired using the same 
imaging protocol within the first 3 days post-SAH, using contiguous slices. Image radiodensity 
threshold was set between 50 and 80 Hounsfield units, and converted to a binary mask. We 
manually drew regions of interest representing subarachnoid and total blood clot on each slice, and 
grouped them into single three-dimensional volumes. 
Statistics 
To evaluate the association between plasma haptoglobin level and HP CNV, we performed separate 
multivariable linear regression modelling in R using the ALSPAC cohort (n=325). We considered 
HP CNV as the exposure and plasma haptoglobin level as the outcome, adjusting for rs2000999 and 
sex.  
For GOSH, we conducted multivariable logistic regression modelling in SPSS v23 and R. A logistic 
regression model was constructed, with mRS as binary dependent variable, and HP CNV, 
rs2000999 and other covariates listed in Table 1 as independent variables. We dichotomized Fisher 
grade into low (I-II) and high (III-IV) as per consensus in aSAH studies. We tested interactions 
between the HP CNV / rs2000999 and other covariates for model fit. Only the HP CNV x Fisher 
category interaction improved model fit (p <0.001).We performed sensitivity analysis with 
progressively decreasing length of follow-up, GOS as outcome, dichotomization of mRS into 
favourable (mRS 0-2) and unfavourable (mRS 3-6) outcomes, and non-dichotomized Fisher grade. 
Multiple imputation was performed using the iterative Markov Chain Monte Carlo method, with 10 
iterations and 2x106 as the initialization value for the Mersenne twister random number generator. 
All variables were used and WFNS was dichotomized. The imputation was repeated for a total of 
five times; imputed values were very similar between the five imputations. Dichotomized mRS was 
regressed on the same variables as in the complete case analysis. One centre with one patient, which 
was missing from the complete case analysis, was also excluded from the imputed case analysis, 
since the quasi-complete separation in data for this centre prevented the logistic regression model 
from converging. 
In the biochemical study, all scalar variables were non-parametric except age, so they were either 
natural log-transformed prior to ANOVA/ANCOVA or analysed with non-parametric tests. We 
performed analysis of covariance in SPSS with maximum ln haemoglobin-haptoglobin complex as 
the dependent variable, ln clot volume, age and maximum ln Qalb as scalar covariates and HP CNV 
genotype and sex as fixed factors. Analyses using mean values for haemoglobin-haptoglobin complex 
and Qalb showed similar results. For all studies, two-tailed hypotheses were tested with alpha = 0.05. 
  
Table 1.  Biospecimen protocol and methodology reporting recommendations 
From: Chou SH, Macdonald RL, Keller E; Unruptured Intracranial Aneurysms and SAH CDE Project Investigators. 
Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common 
Data Elements and Standard Reporting Recommendations. Neurocrit Care. 2019 Jun;30(Suppl 1):46-59. doi: 
10.1007/s12028-019-00725-4.  
Core data element recommendations 
Biological tissue sample source CSF 
Conditions  included/excluded Only aneurysmal SAH was included. Other forms of SAH were excluded. 
Baseline/time‑zero specimen Not applicable; all samples were collected after ictus. 
Site and method of sample acquisition 
CSF was ventricular. CSF was drawn from a 
three way tap connecting the ventricular catheter 
(approximately 30cm long) to the tubing leading 
to an external CSF drainage and monitoring 
system (Becker®, Medtronic). For sampling, the 
tap was opened to the ventricular catheter, and 
closed to the drainage system. The first 3ml of 
CSF (representing dead space) was discarded to 
ensure fresh CSF was obtained. 
Timing of biospecimen collection 
Alternate days from insertion of external 
ventricular drain (EVD) up to two weeks or 
until the EVD was removed 
Type of collection tube Sterile polystyrene 
Method of biospecimen processing 
• Centrifugation to separate supernatant 
from cellular debris and separate storage 
was performed. 
• Parameters: 10 min, soft brakes, 20°C, 
1500 rcf. 
Time lapse between sample collection and 
processing 60 minutes maximum 
Method of biospecimen storage • Storage at − 80°C in cryotubes 
• No freeze/thaw cycles 
 
Supplemental data element recommendations  
Control biospecimens Not applicable 
Convalescent  biospecimens Not applicable 
Serial  biospecimen collection For serial collection, consistent method of 
acquisition including site of acquisition was 
used, to minimize variance in biospecimen and 
biomarker analyses 
Biospecimen storage 
Storage was at -80C in 100/450µL aliqupots 
labelled with printed information (patient ID, 
time post-ictus, sample identity (CSF), sample 
date, volume) and an Excel-based inventory 
system 
Biomarker analysis No freeze/thaw cycles 
Selective inhibitors use Not used 
Biospecimen transport and shipping Samples transferred on dry ice 
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Supplementary Figure 1. mRS and GOS in the analysis population. 
 
 
  
Supplementary Figure 2. Mean predicted probability of favourable outcome (mRS: 0-1) ± 
standard deviation, by HP CNV and undichotomized Fisher grade. Contrasts: (1) At high Fisher: 
p=0.013, Odds ratio = 2.69 (95% CI: 1.2-5.9) for HP2-2 versus HP1-1; (2) At low Fisher: p=0.42, 
Odds ratio = 2.33 (95% CI: 0.30-17.9) for HP2-2 versus HP1-1. Error bars are only shown for 
Fisher I and IV to enhance readability.  
   
       
Supplementary Table 1. Frequencies of HP CNV and rs2000999 genotypes in GOSH and 
ALSPCA cohorts: n (%). 
 HP1-1 HP2-1 HP2-2 Total χ2 vs GOSH 
GOSH 
205 
16% 
612 
47% 
481 
37% 
1298 
100% 
 
ALSPAC 
137 
15% 
418 
45% 
372 
40% 
927 
100% 
NS 
      
 rs2000999 AA rs2000999 AG rs2000999 GG Total χ2 vs GOSH 
GOSH 
57 
5% 
379 
29% 
854 
66% 
1290 
100% 
 
ALSPAC 
34 
4% 
229 
31% 
485 
65% 
748 
100% 
NS 
 
  
Supplementary Table 2. Multivariable linear regression of plasma haptoglobin level versus the HP 
CNV and rs2000999 in the ALSPAC cohort (n=325). HP CNV was considered as the exposure and 
plasma haptoglobin level as the outcome, with adjustment for covariates rs2000999 and sex (model 
fit: r2= 0.23, p = 2.2×10-16). 
 
 Coefficient SE Lower 95% 
CI 
Upper 95% 
CI 
p value 
      
HP CNV -0.2641 0.0354 -0.334 -0.195 8.46×10-13 
rs2000999 -0.1356 0.041 -0.217 -0.054 0.00124 
Sex (reference male) -0.136 0.046 -0.227 -0.045 0.0037 
 
 
  
Supplementary Table 3. Demographics and clinical characteristics of the CSF cohorts. Mean & 
SDa, number and %b. 
 
 High Fisher grade Low Fisher grade 
Collection Prospective Retrospective 
Number 44 8 
Age (years)a 59.8 ± 12.3 52.8 ± 9.0 
Sexb 
male 
female 
 
15 (34%)  
29 (66%) 
 
2 (25%) 
6 (75%) 
Hypertensionb 
Yes 
No 
 
23 (52.3%) 
21 (47.7%) 
 
1 (12.5%) 
7 (87.5%) 
WFNSb 
1 
2 
3 
4 
5 
 
5 (11.4%) 
10 (18%) 
6 (13.6%) 
15 (29.5%) 
8 (13.6%) 
 
7 (87.5%) 
1 (12.5%) 
Fisher gradeb 
1 
2 
3 
4 
 
 
 
2 (4.5%) 
42 (95.5%) 
 
7 (87.5%) 
1 (12.5%) 
Aneurysmal managementb 
Coiled 
Clipped 
Supportive 
 
32 (72.7%) 
5 (11.4%) 
6 (13.6%) 
 
3 (37.5%) 
4 (50%) 
1 (12.5%) 
 
Supplementary Table 4. Analysis after imputation of missing values. Eight variables had missing values (range 0.7-7.4%). The findings were similar 
to the complete case analysis, namely (1) an interaction between HP and Fisher; (2) a protective effect of HP2-2 at high but not low Fisher grade; (3) a 
poor prognostic effect of a high Fisher category was present in HP1-1 but not HP2-2 patients. 
 
 Imputation number Pooled imputation  1 2 3 4 5 
 OR p OR p OR p OR p OR p OR p 
             
Fisher x HP  0.008  0.052  0.014  0.032  0.003   
Fisher 
at HP1-1 
3.9 
(1.6-9.6) 0.003 
3.4 
(1.4-8.1) 0.005 
4.7 
(1.8-12.2) 0.001 
3.1 
(1.3-7.3) 0.008 
3.7 
(1.5-9.2) 0.004 
3.7 
(1.4-9.7) 0.007 
Fisher 
at HP2-2 
0.9 
(0.5-1.5) 0.685 
1.0 
(0.6-1.8) 0.89 
1.0 
(0.6-1.7) 0.987 
0.9 
(0.5-1.6) 0.781 
0.8 
(0.5-1.6) 0.411 
0.9 
(0.5-1.6) 0.799 
HP  0.011  0.046  0.043  0.012  0.025   
HP2-2 vs HP1-1 
at low Fisher grade 
0.5 
(0.2-1.3) 0.151 
0.6 
(0.3-1.4) 0.255 
0.4 
(0.2-1.1) 0.077 
0.7 
(0.3-1.6) 0.373 
0.4 
(0.2-1.1) 0.073 
0.5 
(0.2-1.4) 0.194 
HP2-2 vs HP1-1 
at high Fisher grade 
2.3 
(1.3-4.0) 0.003 
2.0 
(1.2-3.5) 0.013 
2.0 
(1.2-3.5) 0.012 
2.3 
(1.3-4.0) 0.003 
2.1 
(1.2-3.6) 0.009 
2.1 
(1.2-3.8) 0.01 
 
 
